Stock Traders Purchase Large Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw some unusual options trading on Thursday. Investors purchased 27,659 put options on the company. This is an increase of 168% compared to the average volume of 10,336 put options.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $35.45 on Friday. The business’s fifty day moving average price is $33.22 and its 200 day moving average price is $32.72. Teva Pharmaceutical Industries has a 12-month low of $14.99 and a 12-month high of $37.35. The stock has a market capitalization of $40.76 billion, a PE ratio of 59.09, a price-to-earnings-growth ratio of 3.67 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.59%. The firm had revenue of $4.14 billion during the quarter. Equities research analysts forecast that Teva Pharmaceutical Industries will post 1.98 EPS for the current year.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported second-quarter revenue of approximately $4.14 billion, ahead of consensus estimates of $4.02 billion. Innovative medicines grew 43% year over year in local-currency terms, helping offset weaker generics sales. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: Management raised its 2026 revenue outlook to $16.5 billion-$16.9 billion and increased projections for its three key innovative brands, signaling confidence in the company’s branded-drug growth strategy. Teva Outlines Higher 2026 Revenue Outlook
• Positive Sentiment: UZEDY sales reached a record $77 million in the second quarter, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million, supporting optimism about its long-acting injectable portfolio. UZEDY Record Q2 Net Sales
• Positive Sentiment: Piper Sandler reportedly forecast substantial potential appreciation for TEVA, adding to bullish sentiment following the results. Piper Sandler Forecasts Strong Price Appreciation
• Neutral Sentiment: Options activity was unusually elevated: traders bought about 23,688 calls on Wednesday, followed by roughly 27,659 puts on Thursday. The activity indicates heightened speculation but does not establish a clear directional signal. Unusually Large Options Trading
• Negative Sentiment: Second-quarter EPS of $0.02 missed the $0.08 consensus estimate, while acquisition-related costs and impairment charges contributed to a reported net loss of $576 million. Full-year EPS guidance of $1.91-$2.11 also remains below the $2.17 consensus estimate. Teva Q2 Earnings Lag Estimates

Insider Activity

In other news, EVP Richard Daniell sold 30,000 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at approximately $1,973,727. This represents a 34.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the sale, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at $720,576. The trade was a 34.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 300,493 shares of company stock worth $10,537,510. 0.54% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently modified their holdings of TEVA. Aster Capital Management DIFC Ltd bought a new position in Teva Pharmaceutical Industries in the fourth quarter worth about $25,000. Cornerstone Planning Group LLC boosted its stake in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after acquiring an additional 755 shares during the period. Allworth Financial LP grew its holdings in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares during the last quarter. Finally, Global Retirement Partners LLC raised its position in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Truist Financial boosted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.